3 completed, 2 active not recruiting, 1 unknown, 1 withdrawn. 5 Phase 1, 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Active not recruiting 2, Completed 2, Unknown 1 |
| Phase 3 | 2 | Active not recruiting 1, Unknown 1 |
Follow ProQR Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 QR-504a - Fuchs Endothelial Corneal Dystrophy, FECD3 | Phase 1 | Withdrawn | ProQR Therapeutics | 2021-08-10 | 2022-05-11 | |
| An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. sepofarsen - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Unknown | ProQR Therapeutics | 15 | 2021-03-23 | 2022-03-25 |
| A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene QR-1123, Sham procedure - Autosomal Dominant Retinitis Pigmentosa, Eye Diseases | Phase 1 / Phase 2 | Active not recruiting | ProQR Therapeutics | 11 | 2019-10-07 | 2022-05-06 |
| A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) sepofarsen, Sham - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Active not recruiting | ProQR Therapeutics | 36 | 2019-04-04 | 2022-03-17 |
| Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 20 | 2019-03-06 | 2022-04-20 |
| Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation QR-010 - Cystic Fibrosis | Phase 1 | Completed | ProQR Therapeutics | 18 | 2015-09-01 | 2020-09-24 |
| Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients QR-010, Placebo - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 70 | 2015-06-01 | 2019-02-06 |
Eye Diseases (4) · Retinal Diseases (4) · Vision Disorders (4) · Eye Abnormalities (3) · Eye Diseases, Hereditary (3) · Blindness (2) · Cystic Fibrosis (2) · Leber Congenital Amaurosis (2) · Leber Congenital Amaurosis 10 (2) · Meckel Syndrome, Type 4 (2) · Neurologic Manifestations (2) · Retinal Dystrophies (2) · Retinitis Pigmentosa (2) · Sensation Disorders (2) · Corneal Diseases (1)
eluforsen (2) · Intravitreal Injections (1) · salicylhydroxamic acid (1)
United States (5) · Belgium (4) · Canada (4) · France (4) · United Kingdom (4) · Germany (3) · Italy (3) · Brazil (2) · Netherlands (2) · Czechia (1) · Denmark (1) · Spain (1)
John P Clancy, MD (1) · Stuart Elborn, MD (1)
2018 (2)